Recently, we have shown that the KRAS-variant, and other novel inherited mutations like it, appear to predict altered immunity, and possibly autoimmunity.
We first found that individuals with the KRAS-variant are immunosuppressed, resulting in unique responses to cancer therapy1, and likely explaining their increased cancer risk. We also are investigating the impact of the KRAS-variant on the flip-side of immunosuppression, which is autoimmunity, which is also associated with an increased risk of cancer.
Our findings with the KRAS-variant led us to investigate a large panel of genetic biomarkers like the KRAS-variant, which also disrupt microRNA signaling. We have now found that these biomarkers also predict altered immunity, as presented at American Society of Clinical Oncology (ASCO 2017).
MiraKind’s research efforts are currently focused on understanding the impact of these novel mutations, including the KRAS-variant, on altered immunity. Please consider joining one of our studies through taking our research survey. If you are otherwise eligible for KRAS-variant testing, and would like to order testing without joining a study, please follow this link.
TAKE THE ELIGIBILITY SURVEY
By enrolling in a MiraKind study, you can join our efforts to identify cancer prevention and risk-reduction strategies for individuals with the KRAS-variant. Being a study participant is FREE, and you can choose to get your KRAS-variant results for $295.
Spread the Word
We need your help to let people know about the KRAS-variant. Hover over an image to share.
- Weidhaas, J.B., J. Harris, D. Schaue, A. Chen, R. Chin, R. Axelrod, A.K. El-Naggar, A.K. Singh, T.J. Galloway, D. Raben, D. Wang, C. Matthiesen, V. Avizonis, R.R. Manon, O. Yumen, P.F. Nguyen-Tan, A. Trotti, H. Skinner, Q. Zhang, R.L. Ferris, D. Sidransky, and C.H. Chung, The KRAS-variant and Cetuximab Response in Head and Neck Squamous Cell Cancer, A Secondary Analysis of a Randomized Cinical Trial. JAMA Oncology, 2017. 3(4): p. 483-491